|
2017-09-20 |
2017-09-20 |
B
Compra
|
THOMPSON JOHN CRAIG
President & CEO
|
98 633
+48.6%
424,26
1.842.586 US$
|
98 633
+48.6%
|
424,26
|
1.842.586 US$
|
|
|
2017-09-07 |
2017-09-07 |
B
Compra
|
TRUEX PAUL F
|
13 416
+12.1%
351,45
3.455.945 US$
|
13 416
+12.1%
|
351,45
|
3.455.945 US$
|
|
|
2015-11-18 |
2015-11-13 |
Por favor
Venta prevista
|
Hislop Colin
Chief Medical Officer
Oficial
|
87 810
-28.3%
376,35
3.798.842 US$
|
87 810
-28.3%
|
376,35
|
3.798.842 US$
|
|
|
2015-11-12 |
2015-11-11 |
S
Venta
|
Hislop Colin
Chief Medical Officer
Oficial
|
5 000
-20.7%
5,38
26.900 US$
|
5 000
-20.7%
|
5,38
|
26.900 US$
|
|
|
2013-06-26 |
2013-06-24 |
B
Compra
|
Thompson David E.
Consejero no ejecutivo
|
100 000
+354.6%
0,53
53.000 US$
|
100 000
+354.6%
|
0,53
|
53.000 US$
|
|
|
2013-06-04 |
2013-05-31 |
B
Compra
|
DZIURZYNSKI BOGDAN
Consejero no ejecutivo
|
10 000
+inf%
0,59
5.900 US$
|
10 000
+inf%
|
0,59
|
5.900 US$
|
|
|
2013-02-01 |
2013-01-30 |
B
Compra
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
|
5 700 000
+323.5%
0,66
3.762.000 US$
|
5 700 000
+323.5%
|
0,66
|
3.762.000 US$
|
|
|
2013-01-29 |
2013-01-25 |
B
Compra
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
|
1 762 000
+inf%
0,65
1.142.481 US$
|
1 762 000
+inf%
|
0,65
|
1.142.481 US$
|
|
|
2012-07-03 |
2012-06-29 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
|
1 283 300
-100.0%
0,73
942.071 US$
|
1 283 300
-100.0%
|
0,73
|
942.071 US$
|
|
|
2012-07-02 |
2012-06-29 |
B
Compra
|
HENNEY CHRISTOPHER S
Consejero no ejecutivo
|
100 000
+inf%
0,75
74.930 US$
|
100 000
+inf%
|
0,75
|
74.930 US$
|
|
|
2012-07-02 |
2012-06-29 |
B
Compra
|
HENNEY CHRISTOPHER S
Consejero no ejecutivo
|
100 000
+97.6%
0,75
74.930 US$
|
100 000
+97.6%
|
0,75
|
74.930 US$
|
|
|
2012-07-02 |
2012-06-29 |
B
Compra
|
TRUEX PAUL F
President and CEO
Consejero ejecutivo
|
20 000
+3.2%
0,76
15.200 US$
|
20 000
+3.2%
|
0,76
|
15.200 US$
|
|
|
2012-03-22 |
2012-03-22 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
|
1 306 700
-50.5%
2,40
3.140.131 US$
|
1 306 700
-50.5%
|
2,40
|
3.140.131 US$
|
|
|
2012-03-22 |
2012-03-21 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
|
125 000
-4.6%
2,87
358.312 US$
|
125 000
-4.6%
|
2,87
|
358.312 US$
|
|
|
2012-03-22 |
2012-03-20 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
|
116 800
-4.1%
2,90
338.638 US$
|
116 800
-4.1%
|
2,90
|
338.638 US$
|
|
|
2012-01-03 |
2011-12-30 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
280
-0.6%
6,23
1.743 US$
|
280
-0.6%
|
6,23
|
1.743 US$
|
|
|
2012-01-03 |
2011-12-30 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
4 090
-0.6%
6,23
25.460 US$
|
4 090
-0.6%
|
6,23
|
25.460 US$
|
|
|
2012-01-03 |
2011-12-30 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
280
-0.6%
6,23
1.743 US$
|
280
-0.6%
|
6,23
|
1.743 US$
|
|
|
2012-01-03 |
2011-12-30 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
4 090
-0.6%
6,23
25.460 US$
|
4 090
-0.6%
|
6,23
|
25.460 US$
|
|
|
2012-01-03 |
2011-12-30 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
20 630
-0.6%
6,23
128.422 US$
|
20 630
-0.6%
|
6,23
|
128.422 US$
|
|
|
2012-01-03 |
2011-12-30 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
20 630
-0.6%
6,23
128.422 US$
|
20 630
-0.6%
|
6,23
|
128.422 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
280
-0.6%
6,22
1.743 US$
|
280
-0.6%
|
6,22
|
1.743 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
4 090
-0.6%
6,22
25.457 US$
|
4 090
-0.6%
|
6,22
|
25.457 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
20 630
-0.6%
6,22
128.405 US$
|
20 630
-0.6%
|
6,22
|
128.405 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
280
-0.6%
6,22
1.743 US$
|
280
-0.6%
|
6,22
|
1.743 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
4 090
-0.6%
6,22
25.457 US$
|
4 090
-0.6%
|
6,22
|
25.457 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
20 630
-0.6%
6,22
128.405 US$
|
20 630
-0.6%
|
6,22
|
128.405 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
280
-0.6%
6,51
1.823 US$
|
280
-0.6%
|
6,51
|
1.823 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
4 090
-0.6%
6,51
26.629 US$
|
4 090
-0.6%
|
6,51
|
26.629 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
280
-0.6%
6,51
1.823 US$
|
280
-0.6%
|
6,51
|
1.823 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
4 090
-0.6%
6,51
26.629 US$
|
4 090
-0.6%
|
6,51
|
26.629 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
HEALY JAMES
Consejero no ejecutivo
Gran accionista
|
20 630
-0.6%
6,51
134.318 US$
|
20 630
-0.6%
|
6,51
|
134.318 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
SOFINNOVA VENTURE PARTNERS VI L P
Gran accionista
|
20 630
-0.6%
6,51
134.318 US$
|
20 630
-0.6%
|
6,51
|
134.318 US$
|
|
|
2011-12-13 |
2011-12-13 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
|
16 200
-0.6%
6,50
105.300 US$
|
16 200
-0.6%
|
6,50
|
105.300 US$
|
|
|
2011-12-13 |
2011-12-09 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
|
40 000
-1.4%
6,75
270.000 US$
|
40 000
-1.4%
|
6,75
|
270.000 US$
|
|
|
2011-11-18 |
2011-11-18 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
3 000
-0.1%
6,50
19.500 US$
|
3 000
-0.1%
|
6,50
|
19.500 US$
|
|
|
2011-11-18 |
2011-11-17 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
24 000
-0.8%
6,67
160.080 US$
|
24 000
-0.8%
|
6,67
|
160.080 US$
|
|
|
2011-11-18 |
2011-11-16 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
25 000
-0.9%
6,87
171.750 US$
|
25 000
-0.9%
|
6,87
|
171.750 US$
|
|
|
2011-11-17 |
2011-11-15 |
Por favor
Venta prevista
|
TRUEX PAUL F
President and CEO
Consejero ejecutivo
|
15 000
-2.2%
6,96
104.352 US$
|
15 000
-2.2%
|
6,96
|
104.352 US$
|
|
|
2011-11-17 |
2011-11-15 |
Por favor
Venta prevista
|
TRUEX PAUL F
President and CEO
Consejero ejecutivo
|
15 000
-2.2%
6,96
104.352 US$
|
15 000
-2.2%
|
6,96
|
104.352 US$
|
|
|
2011-11-15 |
2011-11-15 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
50 000
-1.7%
6,93
346.500 US$
|
50 000
-1.7%
|
6,93
|
346.500 US$
|
|
|
2011-11-15 |
2011-11-14 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
5 000
-0.2%
6,95
34.750 US$
|
5 000
-0.2%
|
6,95
|
34.750 US$
|
|
|
2011-11-15 |
2011-11-11 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
5 000
-0.2%
7,14
35.700 US$
|
5 000
-0.2%
|
7,14
|
35.700 US$
|
|
|
2011-11-10 |
2011-11-08 |
S
Venta
|
Hislop Colin
Chief Medical Officer
Oficial
|
15 000
-20.6%
6,74
101.163 US$
|
15 000
-20.6%
|
6,74
|
101.163 US$
|
|
|
2011-10-25 |
2011-10-21 |
Por favor
Venta prevista
|
TRUEX PAUL F
President and CEO
Consejero ejecutivo
|
11 879
-1.8%
6,25
74.244 US$
|
11 879
-1.8%
|
6,25
|
74.244 US$
|
|
|
2011-08-04 |
2011-08-02 |
Por favor
Venta prevista
|
LOWE CHRISTOPHER P.
Chief Financial Officer & CBO
Oficial
|
300
-6.1%
7,93
2.378 US$
|
300
-6.1%
|
7,93
|
2.378 US$
|
|
|
2011-06-20 |
2011-06-16 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
10
-0.1%
8,67
87 US$
|
10
-0.1%
|
8,67
|
87 US$
|
|
|
2011-06-20 |
2011-06-16 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
281
-0.1%
8,67
2.436 US$
|
281
-0.1%
|
8,67
|
2.436 US$
|
|
|
2011-06-20 |
2011-06-16 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
2 809
-0.1%
8,67
24.354 US$
|
2 809
-0.1%
|
8,67
|
24.354 US$
|
|
|
2011-06-17 |
2011-06-15 |
Por favor
Venta prevista
|
TRUEX PAUL F
President and CEO
Consejero ejecutivo
|
15 000
-2.2%
8,30
124.539 US$
|
15 000
-2.2%
|
8,30
|
124.539 US$
|
|
|
2011-06-15 |
2011-06-14 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
2
-0.0%
8,81
18 US$
|
2
-0.0%
|
8,81
|
18 US$
|
|
|
2011-06-15 |
2011-06-14 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
63
-0.0%
8,81
555 US$
|
63
-0.0%
|
8,81
|
555 US$
|
|
|
2011-06-15 |
2011-06-14 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
634
-0.0%
8,81
5.586 US$
|
634
-0.0%
|
8,81
|
5.586 US$
|
|
|
2011-06-15 |
2011-06-13 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
4
-0.0%
8,80
35 US$
|
4
-0.0%
|
8,80
|
35 US$
|
|
|
2011-06-15 |
2011-06-13 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
118
-0.0%
8,80
1.038 US$
|
118
-0.0%
|
8,80
|
1.038 US$
|
|
|
2011-06-15 |
2011-06-13 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
1 178
-0.0%
8,80
10.366 US$
|
1 178
-0.0%
|
8,80
|
10.366 US$
|
|
|
2011-06-10 |
2011-06-10 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
30 000
-1.0%
8,18
245.400 US$
|
30 000
-1.0%
|
8,18
|
245.400 US$
|
|
|
2011-06-10 |
2011-06-09 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
37 000
-1.2%
8,11
300.070 US$
|
37 000
-1.2%
|
8,11
|
300.070 US$
|
|
|
2011-06-10 |
2011-06-08 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
33 000
-1.1%
8,02
264.660 US$
|
33 000
-1.1%
|
8,02
|
264.660 US$
|
|
|
2011-05-31 |
2011-05-26 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
16
-0.1%
8,60
138 US$
|
16
-0.1%
|
8,60
|
138 US$
|
|
|
2011-05-31 |
2011-05-26 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
435
-0.1%
8,60
3.741 US$
|
435
-0.1%
|
8,60
|
3.741 US$
|
|
|
2011-05-31 |
2011-05-26 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
4 349
-0.1%
8,60
37.401 US$
|
4 349
-0.1%
|
8,60
|
37.401 US$
|
|
|
2011-05-27 |
2011-05-25 |
S
Venta
|
ORBIMED ADVISORS LLC
Consejero no ejecutivo
Gran accionista
|
4 800
8,65
41.520 US$
|
4 800
|
8,65
|
41.520 US$
|
|
|
2011-05-25 |
2011-05-25 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
108
-0.6%
8,67
936 US$
|
108
-0.6%
|
8,67
|
936 US$
|
|
|
2011-05-25 |
2011-05-25 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
2 970
-0.6%
8,67
25.750 US$
|
2 970
-0.6%
|
8,67
|
25.750 US$
|
|
|
2011-05-25 |
2011-05-25 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
29 672
-0.6%
8,67
257.256 US$
|
29 672
-0.6%
|
8,67
|
257.256 US$
|
|
|
2011-05-25 |
2011-05-24 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
172
-1.0%
8,42
1.448 US$
|
172
-1.0%
|
8,42
|
1.448 US$
|
|
|
2011-05-25 |
2011-05-24 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
4 734
-1.0%
8,42
39.860 US$
|
4 734
-1.0%
|
8,42
|
39.860 US$
|
|
|
2011-05-25 |
2011-05-24 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
47 290
-1.0%
8,42
398.182 US$
|
47 290
-1.0%
|
8,42
|
398.182 US$
|
|
|
2011-05-25 |
2011-05-23 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
88
-0.5%
8,18
720 US$
|
88
-0.5%
|
8,18
|
720 US$
|
|
|
2011-05-25 |
2011-05-23 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
2 422
-0.5%
8,18
19.812 US$
|
2 422
-0.5%
|
8,18
|
19.812 US$
|
|
|
2011-05-25 |
2011-05-23 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
24 193
-0.5%
8,18
197.899 US$
|
24 193
-0.5%
|
8,18
|
197.899 US$
|
|
|
2011-05-19 |
2011-05-19 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
412
-2.2%
8,03
3.308 US$
|
412
-2.2%
|
8,03
|
3.308 US$
|
|
|
2011-05-19 |
2011-05-19 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
11 337
-2.2%
8,03
91.036 US$
|
11 337
-2.2%
|
8,03
|
91.036 US$
|
|
|
2011-05-19 |
2011-05-19 |
S
Venta
|
VANTAGEPOINT VENTURE ASSOCIATES IV LLC
Gran accionista
|
113 251
-2.2%
8,03
909.406 US$
|
113 251
-2.2%
|
8,03
|
909.406 US$
|
|